Boston Scientific exec to head JenaValve
This article was originally published in Clinica
Executive Summary
German transcatheter aortic valve developer JenaValve has appointed Boston Scientific alumna Victoria Carr-Brendel CEO. Dr Carr-Brendel replaces Jans Keltjens, who took the helm on an interim basis after David Drachman left the post in January this year; Mr Drachman resigned after only six months as CEO due to “non-business-related personal reasons”. Mr Keltjens will remain chairman of the JenaValve board and support Dr Carr-Brendel during the transition period.